DOI: http://dx.doi.org/10.18203/issn.2454-5929.ijohns20173037

Medical management of oral submucous fibrosis

Anjana Agrawal, Yashaswi Kaushal, Sudhakar Vaidya, Kriti Shrivastava

Abstract


Background: In 1952 Schwartz coined the term “atrophica idiopathica mucosa oris” to describe an oral fibrosing disease he discovered in 5 Indian women from Kenya. Oral submucous fibrosis of oral cavity is a chronic progressive debilitating disease and premalignant condition of oral cavity. The condition is well recognized for its malignant potential and it is particularly associated with aracanut chewing. It is characterized by burning sensation in mouth particularly while eating spicy food and progressive development of inability to open mouth. Worldwide estimate of oral submucous fibrosis indicate that 2.5 million people are affected with a higher incidence in Indian subcontinent.

Methods: This is an observational type of study of 100 patients with oral submucous fibrosis attending ENT OPD.  

Results: We observed that with effective combination of treatment and avoiding predisposing factors and with long time follow-up we got markedly good results.

Conclusions: Although medical management does not completely cure the disease but optimal doses of injection corticosteroid with injection hyaluronidase with avoidance of predisposing factors and improvement of dietary habit with prolong follow up is effective in some extent.


Keywords


Submucous fibrosis, Arecanut, Injection Hyaluronidase, Injection triamcinolone

Full Text:

PDF

References


Cox SC, Walker DM. Oral submucous fibrosis: a review. Aust Dent J. 1996;41(5):294-9.

Ibsen O, Phelan J. Inflamation and repair in oral pathology for dental hygienists, Oral Pathology for the Dental Hygienist. WB saunder’s Co; 1992: 76-79.

Gupta SC. “Mist” an aetiological factor in oral submucosal fibrosis. Indian J Otolaryngol. 1978;30(1):5-6.

Coman DR, Mccutcheon M, Zeidman I. Failure of hyaluronidase to increase in invasiveness of neoplasms. Cancer Res. 1947;7(6):383–5.

Pathak AG. Fibrin producing factor in OSMF. Indian J Otolaryngol. 1979;31(4):103–4.

Shah N, Sharma PP. Role of chewing and smoking habits in the etiology of oral submucous fibrosis (OSF): A case control study. J Oral Pathol Med. 1998;27:475–9.

DeWaal J, Olivier A, van Wyk CK, Maritz JS. The fibroblast population in oral submucous fibrosis. J Oral Pathol Med. 1997;26:69–74.

Singh GP, Rizvi I, Gupta V, Bains VK. Influence of smokeless tobacco on periodontal health status in local population of north India: A cross sectional study. Dent Res J (Isfahan). 2011;8:211–20.

Ghom AG, Gupta M, Deoghare A, Diwan R, Khandelwal A, Gandhi A. Comparison between Efficacy of Hydrocortisone / Hyaluronidase and Triamcinolone / Hyaluronidase in Combination with Lycopene / Pentoxifylline / Placebo Oral Supplementation in Treatment of Trismus in OSMF Patients. Chhattisgarh J Health Sci. 2013;1(1):8-11.

Bhuvana K, Khan M. Management of oral submucous fibrosis by two different drug regimens: A comparative study. Dent Res J (Isfahan). 2013;10(4):527–32.

Aara A, Satishkumar GP, Vani C, Reddy VM, Sreekanth K, Ibrahim M. Comparative Study of Intralesional Dexamethasone, Hyaluronidase and Oral Pentoxifylline in Patients with Oral Submucous Fibrosis. Global J Med Res. 2012;12(7):1-15.

James L, Shetty A, Rishi D, Abraham M. Management of Oral Submucous Fibrosis with Injection of Hyaluronidase and Dexamethasone in Grade III Oral Submucous Fibrosis: A Retrospective Study. J Int Oral Health. 2015;7(8):82–5.

Ameer NT, Shukla RK. A Cross Sectional Study of Oral Submucous Fibrosis in central india and the effect of local Triamcinolone therapy. Indian J Otolaryngol Head Neck Surg. 2012;64(3):240-3.